Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1700289
10 August 2023 07:24AM

CompuGroup Medical launches AI initiative improving healthcare IT products and solutions


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous
CompuGroup Medical launches AI initiative improving healthcare IT products and solutions

10.08.2023 / 07:24 CET/CEST
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical launches AI initiative improving healthcare IT products and solutions

 

  • CGM AI Initiative launched in the second quarter
  • More face-to-face time with patients for doctors and healthcare practitioners
  • Strengthening R&D and business operations with high data protection standards
  • Continued investments into new technologies for the benefit of our customers
  • CGM well prepared for next level digital development in healthcare IT


Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, has launched an initiative in the second quarter to further extend the usage of Artificial Intelligence (AI), machine learning and large language models across the group. While already today several of CGM’s products and solutions are relying on AI based functions, there is significant potential for AI to shape and change the healthcare IT sector in the coming years. The benefits for doctors, healthcare practitioners, and patients are significant. Core AI fields for CGM customers range from chronic care management, prevention, diagnostics, population health management to improving operations and resource management, a key topic for doctors. Studies show that doctors and their teams spend 3-4 hours of administrative work for every hour actually dedicated to the wellbeing of their patients – AI based solutions will further reduce the inefficiencies in the healthcare ecosystem for the benefit of patients.

AI has been pushed as a key management priority at CGM. The team is focusing on the increasing use of Artificial Intelligence in products and solutions, to further enable the intelligent use of data while maintaining high data protection standards. At CGM, the new AI technology will be integrated into relevant areas and processes, from software development towards support processes, including customer service functions and administrative tasks.

When announcing the figures for the first half year 2023, CEO & CFO Michael Rauch described AI as a differentiating factor that will shape and change the healthcare IT sector in the coming years. Wisely used and safeguarding data privacy, AI offers significant advantages for doctors, hospitals, pharmacies, and patients. “The majority of patients trust Artificial Intelligence to support the doctor and would be willing to share their data for this purpose. We will help our customers making the difference, enabling them to spend more time with their patients, having sophisticated tools on their hands to improve healthcare.” says CEO & CFO Michael Rauch. “CGM is fully committed to deliver on our mission: We create the future of e-health.”

For the first half of 2023, CompuGroup Medical reported strong results across all segments. Group revenue increased by 15 % to EUR 595 million, with organic growth at 12 % compared to prior year. CGM continues to invest into research and development to drive innovation and to advance technology in the healthcare sector and confirms its guidance for 2023 with expected organic growth in group revenues of around 5 %.

 

Financial key figures

kEUR  Q2 2023  Q2 2022  Change  01.01.-30.06.2023  01.01.-30.06.2022  Change 
Revenues  304,179  265,047  + 15 %  595,022  516,696  + 15 % 
Recurring revenues in %  66 %  68 %  - 2 ppt  67 %  69 %  - 2 ppt 
Organic growth in %  13 %  3 %  + 10 ppt  12 %  4 %  + 8 ppt 
EBITDA adjusted  73,144  53,594  + 36 %  133,093  105,110  + 27 % 
EBITDA margin adjusted  24 %  20 %  + 4 ppt  22 %  20 %  + 2 ppt 
EPS adjusted (EUR) - diluted  0.62  0.40  + 55 %  1.07  0.82  + 30 % 
Free cash flow  4,031  - 36,492  + 111 %  82,534  28,117  + 194 % 
Number of shares outstanding (‘000)        52,235  52,235  + 0 % 

 

The full half-year financial report is available on the company's website at www.cgm.com/ir-publications.


About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.130 billion in 2022, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals, and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 21 countries and products in 60 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.



10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1700289

 
End of News EQS News Service

1700289  10.08.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1700289&application_name=news&site_id=boersengefluester
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.